Literature DB >> 15324322

Neonatal salt-wasting and 11 beta-hydroxylase deficiency in a child carrying a homozygous deletion hybrid CYP11B2 (aldosterone synthase)-CYP11B1 (11 beta-hydroxylase).

B Ezquieta1, Cristina Luzuriaga.   

Abstract

This article reports the case of a boy diagnosed at 1.8 years of age with congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. The patient showed salt-wasting episodes during the neonatal period. On molecular analysis, a homozygous deletion hybrid (CYP11B2-CYP11B1) involving the CYP11B locus at 8q24.3 was found. Southern blot analysis showed the break point of the chimera gene to be located before intron 5; sequence analysis identified it at exon 4 between codons 202 and 248. This CYP11B2(5')/B1(3') hybrid should lack aldosterone synthase activity (due to the CYP11B1 residues at exons 5 and 6), and the enzyme it codes for should not be promoted by adrenocorticotropic hormone (ACTH) (CYP11B2 promoter sequences). The patient phenotype - neonatal salt-wasting and 11 beta-hydroxylase deficiency - is in agreement with this hybrid structure. This is the first time a homozygous deletion hybrid generated by unequal crossover has been described in exon 4. This genetic lesion appears to be the reciprocal product from the recombination event that causes glucocorticoid-remediable aldosteronism, a duplication dominant allele (CYP11B2-CYP11B1/B2-CYP11B1) coding for additional aldosterone synthase activity regulated by ACTH. The clinical presentation of the condition in this patient contributes to the in vivo understanding of the regulation of this complex locus in which two 'duplicated' genes have evolved different regulatory and enzymatic activities involved in mineralocorticoid and glucocorticoid synthesis in the adrenal glands. The fact that this allele was first predicted and has now been documented clinically and molecularly in vivo is particularly noteworthy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324322     DOI: 10.1111/j.1399-0004.2004.00291.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

Review 1.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

2.  Detection of Small CYP11B1 Deletions and One Founder Chimeric CYP11B2/CYP11B1 Gene in 11β-Hydroxylase Deficiency.

Authors:  Hua Xie; Hui Yin; Xue Ye; Ying Liu; Na Liu; Yu Zhang; Xiaoli Chen; Xiaobo Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-24       Impact factor: 6.055

3.  Improving the diagnosis of 11β-hydroxylase deficiency using home-made MLPA probes: identification of a novel chimeric CYP11B2/CYP11B1 gene in a Sicilian patient.

Authors:  S Menabò; S Boccassini; A Gambineri; A Balsamo; R Pasquali; O Prontera; L Mazzanti; L Baldazzi
Journal:  J Endocrinol Invest       Date:  2015-08-18       Impact factor: 4.256

Review 4.  Insights on the phenotypic heterogenity of 11β-hydroxylase deficiency: clinical and genetic studies in two novel families.

Authors:  Luciana Pinto Valadares; Alessandra Christine Vieira Pfeilsticker; Selma Moreira de Brito Sousa; Sarah Caixeta Cardoso; Olivia Laquis de Moraes; Luiz Claudio Gonçalves de Castro; Renata Santarem de Oliveira; Adriana Lofrano-Porto
Journal:  Endocrine       Date:  2018-09-21       Impact factor: 3.633

5.  Roux-en-Y gastric bypass in the treatment of non-classic congenital adrenal hyperplasia due to 11-hydroxylase deficiency.

Authors:  Amir Kalani; Nithin Thomas; Alan Sacerdote; Gül Bahtiyar
Journal:  BMJ Case Rep       Date:  2013-03-18

6.  Mineralocorticoid hypertension.

Authors:  Vishal Gupta
Journal:  Indian J Endocrinol Metab       Date:  2011-10

Review 7.  Molecular Diagnosis of Steroid 21-Hydroxylase Deficiency: A Practical Approach.

Authors:  María Arriba; Begoña Ezquieta
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.